BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Endocrine gland cancer AND FH, HLRCC, 2271, ENSG00000091483, MCUL1, MCL, LRCC, P07954
315 results:

  • 1. TCEB3 initiates ovarian cancer apoptosis by mediating ubiquitination and degradation of mcl-1.
    Cai Y; Li Y; Xu Y; Yang W; Huang M
    FASEB J; 2024 Apr; 38(8):e23625. PubMed ID: 38661028
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. WP1066, a small molecule inhibitor of STAT3, chemosensitizes paclitaxel-resistant ovarian cancer cells to paclitaxel by simultaneously inhibiting the activity of STAT3 and the interaction of STAT3 with Stathmin.
    Yang J; Li N; Zhao X; Guo W; Wu Y; Nie C; Yuan Z
    Biochem Pharmacol; 2024 Mar; 221():116040. PubMed ID: 38311257
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Pancreatic Metastasectomy for Secondary Malignancy of the Pancreas: A Single-institution Experience.
    Lee O; Yoon SK; Yoon SJ; Kim H; Han IW; Heo JS; Shin SH
    Anticancer Res; 2024 Feb; 44(2):703-710. PubMed ID: 38307567
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. What We Know about and What Is New in Primary Aldosteronism.
    Ekman N; Grossman AB; Dworakowska D
    Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38255973
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Pan-EGFR Inhibitor Dacomitinib Resensitizes Paclitaxel and Induces Apoptosis via Elevating Intracellular ROS Levels in Ovarian cancer SKOV3-TR Cells.
    Lim YJ; Kim HS; Bae S; So KA; Kim TJ; Lee JH
    Molecules; 2024 Jan; 29(1):. PubMed ID: 38202856
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Acute mast cell leukemia without KIT D816V mutation and lack of CD2 and CD25-a case report of rare entity.
    Zaremba-Pataj E; Patkowska E; Krzywdzińska A; Szumera-Ciećkiewicz A; Chlebowska-Tuz J
    J Hematop; 2023 Mar; 16(1):39-47. PubMed ID: 38175371
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. The connection between tricarboxylic acid cycle enzyme mutations and pseudohypoxic signaling in pheochromocytoma and paraganglioma.
    Wang Y; Liu B; Li F; Zhang Y; Gao X; Wang Y; Zhou H
    Front Endocrinol (Lausanne); 2023; 14():1274239. PubMed ID: 37867526
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Clinicopathologic Analysis and Molecular Profiling of Ovarian Steroid Cell Tumors.
    Mendoza RP; Wang P; Smith HL; Fitzpatrick CA; Haridas R; Wanjari P; Briese R; Shahid A; McCluggage WG; Bennett JA
    Am J Surg Pathol; 2023 Dec; 47(12):1398-1408. PubMed ID: 37796179
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Bcl-2 family inhibitors sensitize human cancer models to therapy.
    Valentini E; Di Martile M; Brignone M; Di Caprio M; Manni I; Chiappa M; Sergio I; Chiacchiarini M; Bazzichetto C; Conciatori F; D'Aguanno S; D'Angelo C; Ragno R; Russillo M; Colotti G; Marchesi F; Bellone ML; Dal Piaz F; Felli MP; Damia G; Del Bufalo D
    Cell Death Dis; 2023 Jul; 14(7):441. PubMed ID: 37460459
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. A Pancreatic Collision Tumor Comprising Mantle Cell Lymphoma and Adenocarcinoma: A Case Report and Literature Review.
    Sugaya R; Taniguchi A; Abe M; Ozawa I; Kirito K; Hatakeyama S
    Intern Med; 2024 Feb; 63(4):553-558. PubMed ID: 37380453
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Curcumin reduces paclitaxel resistance in ovarian carcinoma cells by upregulating SNIP1 and inhibiting NFκB activity.
    Huang SL; Chang TC; Sun NK
    Biochem Pharmacol; 2023 Jun; 212():115581. PubMed ID: 37146834
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. PD-L1 and mcl-1 markers and the relationship with prognostic characteristics of differentiated thyroid carcinoma.
    Zantut-Wittmann DE; Barreto IS; Laus AC; Moreno DA; Moma CA; Maia FFR; Assumpção LVMD; Reis RM
    Mol Cell Endocrinol; 2023 Jun; 570():111931. PubMed ID: 37072108
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. USP9X mediates an acute adaptive response to MAPK suppression in pancreatic cancer but creates multiple actionable therapeutic vulnerabilities.
    Perurena N; Lock R; Davis RA; Raghavan S; Pilla NF; Ng R; Loi P; Guild CJ; Miller AL; Sicinska E; Cleary JM; Rubinson DA; Wolpin BM; Gray NS; Santagata S; Hahn WC; Morton JP; Sansom OJ; Aguirre AJ; Cichowski K
    Cell Rep Med; 2023 Apr; 4(4):101007. PubMed ID: 37030295
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Metabolomics in paraganglioma: applications and perspectives from genetics to therapy.
    Richter S; Garrett TJ; Bechmann N; Clifton-Bligh RJ; Ghayee HK
    Endocr Relat Cancer; 2023 Jun; 30(6):. PubMed ID: 36897220
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Fumarate Hydratase Variants and Their Association With Paraganglioma/Pheochromocytoma.
    Zavoshi S; Lu E; Boutros PC; Zhang L; Harari A; Hatchell KE; Nielsen SM; Esplin ED; Ouyang K; Nykamp K; Wilde B; Christofk H; Shuch B
    Urology; 2023 Jun; 176():106-114. PubMed ID: 36773955
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. A secondary CD34+ acute lymphoblastic leukemia unmasked and mobilized by G-CSF in an autologous stem cell donor with testicular cancer.
    Cooling L; Kelley J; Sexton E; Anand S; Hoffmann S
    Transfusion; 2023 Apr; 63(4):684-689. PubMed ID: 36762622
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Design, synthesis and biological evaluation of 2-((4-sulfamoylphenyl)amino)-pyrrolo[2,3-d]pyrimidine derivatives as CDK inhibitors.
    Yang B; Quan Y; Zhao W; Ji Y; Yang X; Li J; Li Y; Liu X; Wang Y; Li Y
    J Enzyme Inhib Med Chem; 2023 Dec; 38(1):2169282. PubMed ID: 36656085
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. The antitumor effect of the novel agent mcl/ACT001 in pancreatic ductal adenocarcinoma.
    Yang J; Li Y; Han X; Pei X; Lin Z; Li C
    J Cancer Res Clin Oncol; 2023 Aug; 149(9):5717-5728. PubMed ID: 36547690
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Proteogenomic insights into the biology and treatment of pancreatic ductal adenocarcinoma.
    Tong Y; Sun M; Chen L; Wang Y; Li Y; Li L; Zhang X; Cai Y; Qie J; Pang Y; Xu Z; Zhao J; Zhang X; Liu Y; Tian S; Qin Z; Feng J; Zhang F; Zhu J; Xu Y; Lou W; Ji Y; Zhao J; He F; Hou Y; Ding C
    J Hematol Oncol; 2022 Nov; 15(1):168. PubMed ID: 36434634
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Evaluation of family history in individuals with heterozygous BRCA pathogenic variants diagnosed with breast or ovarian cancer in a single center in Italy.
    Negri S; De Ponti E; Sina FP; Sala E; Dell'Oro C; Roversi G; Lazzarin S; Delle Marchette M; Inzoli A; Toso C; Fumagalli S; Campanella M; Kotsopoulos J; Fruscio R
    Mol Genet Genomic Med; 2022 Dec; 10(12):e2071. PubMed ID: 36307994
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 16.